42 studies found for:    Open Studies | "Unrelated Donors"
Show Display Options
Rank Status Study
21 Recruiting Pilot Study of Reduced-Intensity Hematopoietic Stem Cell Transplant of DOCK8 Deficiency
Condition: DOCK8 Deficiency
Interventions: Procedure: Reduced-intensity hematopoietic stem cell;   Drug: Fludarabine(Fludara, Berlex Laboratories);   Drug: Cyclophosphamide(CTX, Cytoxan);   Procedure: Total Body Irradiation (TBI);   Drug: Busulfan (Busulfex)
22 Recruiting Combined Cord Blood Transplant
Conditions: Acute Leukemia;   Immune Deficiency Disorder;   Congenital Hematological Disorder;   Metabolism Disorder;   Aplastic Anemia;   Myelodysplastic Syndromes;   Chronic Leukemia;   Lymphoma;   Multiple Myeloma;   Solid Tumor
Interventions: Radiation: Total Body Irradiation 1200 cGy;   Radiation: Total Body Irradiation 200 cGy;   Drug: Cyclophosphamide;   Drug: Mesna;   Procedure: Cord Blood Infusion;   Drug: Busulfan;   Drug: Fludarabine;   Drug: Melphalan
23 Recruiting Expanded Access Protocol Using CD3+/CD19+ Depleted PBSC
Conditions: Leukemia;   Inborn Errors of Metabolism;   Bone Marrow Failure Syndromes;   Immunodeficiencies;   Immunodysregulation Polyendocrinopathy Enteropathy X-linked Syndrome
Intervention: Device: Transplant of stem cells with CD3+/CD19+ depletion (CliniMACs)
24 Recruiting Allogeneic Stem Cell Transplantation for Patients With Severe Aplastic Anemia
Condition: Anemia, Aplastic
Intervention: Drug: Cyclophosphamide,Campath IH and TBI
25 Recruiting Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft vs Host Disease Following Unrelated Stem Cell Transplant
Conditions: Graft vs Host Disease;   Hematologic Neoplasms;   Non-Neoplastic Hematologic and Lymphocytic Disorder
Interventions: Drug: Vorinostat;   Drug: Tacrolimus;   Drug: Methotrexate
26 Not yet recruiting UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
Conditions: Acute Leukemia;   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia/Lymphoma;   Burkitt's Lymphoma;   Natural Killer Cell Malignancies;   Chronic Myelogenous Leukemia;   Myelodysplastic Syndrome;   Large-cell Lymphoma;   Hodgkin Lymphoma;   Multiple Myeloma;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Marginal Zone B-cell Lymphoma;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle-cell Lymphoma;   Prolymphocytic Leukemia;   Bone Marrow Failure Syndromes;   Myeloproliferative Syndromes
Interventions: Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: MMF;   Drug: Sirolimus;   Radiation: TBI;   Biological: Umbilical cord blood cell infusion;   Biological: ATG
27 Recruiting Alpha/Beta T and CD19+ Depleted Peripheral Stem Cells for Patients With Primary Immunodeficiencies
Conditions: Immunodeficiencies;   Immune Dysregulation Syndromes
Intervention: Device: Apha/beta T and CD19+ cell depletion using CliniMACS device
28 Recruiting Donor Stem Cell Transplantation for Congenital Immunodeficiencies
Condition: Inherited Immune Deficiencies
Interventions: Drug: Fludarabine;   Drug: Total Body Irradiation, Busulfan, Campath-1H, or h-ATG, Fludarabine;   Drug: Sirolimus or equivalent based on response;   Drug: Granulocyte Colony Stimulating Factor (G-CSF);   Other: hematopoietic progenitor cells
29 Recruiting Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant
Condition: Acute Myeloid Leukemia
Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Clofarabine;   Drug: Cyclosporine;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Pharmacological Study;   Radiation: Total-Body Irradiation
30 Recruiting Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression
Condition: Graft Versus Host Disease
Intervention: Drug: Tacrolimus and MMF.
31 Recruiting NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia
Conditions: Severe Aplastic Anemia;   Aplastic Anemia;   Bone Marrow Failure;   Immunosuppression
Interventions: Drug: Thymoglobulin;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total body irradiation;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil
32 Recruiting Haematopoietic Stem Cell Transplantation (HSCT) in Comparison to Conventional Consolidation Therapy for Patients With Acute Myeloid Leukemia (AML) (Intermediate Risk) <= 60y. After First CR
Condition: Leukemia, Myeloid, Acute
Interventions: Biological: Human Stem Cell Transplantation;   Drug: Consolidation chemotherapy, i.e. High-dose Cytarabine (HiDAC)
33 Recruiting HCT Versus CT in Elderly AML
Condition: Acute Myeloid Leukemia
Interventions: Procedure: hematopoietic cell transplantation;   Drug: Non-Transplant treatment approach for consolidation
34 Recruiting Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis
Conditions: Leukemia;   Lymphoma;   Myelodysplastic Syndrome;   Myelofibrosis;   Severe Aplastic Anemia;   Allogeneic Transplant
Intervention: Drug: Cyclophosphamide
35 Recruiting Evaluation of 3 Different Doses of IV Busulfan
Conditions: Myelodysplastic Syndrome;   Acute Myeloid Leukemia
Interventions: Drug: BX2;   Drug: BX3;   Drug: BX4
36 Not yet recruiting High Resolution Donor Recipient HLA Matching Level in Unrelated HSCT
Condition: Hematologic Diseases
Intervention:
37 Recruiting Carfilzomib for the Prevention of Graft Versus Host Disease
Condition: Graft-versus-host Disease
Intervention: Drug: carfilzumib
38 Recruiting High Dose Peripheral Blood Stem Cell Transplantation With Post Transplant Cyclophosphamide for Patients With Chronic Granulomatous Disease
Condition: X-Linked Chronic Granulomatious Disease
Interventions: Drug: Campath;   Drug: Busulfan;   Other: allogeneic peripheral blood allograft infusion;   Drug: cyclophosphamide
39 Recruiting Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases
Conditions: Severe Combined Immunodeficiency (SCID);   Immunodeficiency With Predominant T-cell Defect, Unspecified;   Severe Chronic Neutropenia;   Chronic Granulomatous Disease (CGD);   Hyper IgE Syndromes;   Hyper IgM Deficiencies;   Wiskott-Aldrich Syndrome;   Mendelian Susceptibility to Mycobacterial Disease;   Common Variable Immune Deficiency (CVID)
Intervention: Biological: CD3/CD19 negative allogeneic hematopoietic stem cells
40 Recruiting CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant
Conditions: Chronic Myeloid Leukemia (CML);   Acute Myelogenous Leukemia (AML);;   Myelodysplastic Syndrome (MDS);;   Juvenile Myelomonocytic Leukemia (JMML);;   Acute Lymphoblastic Leukemia (ALL);;   Lymphoma (Hodgkin's and Non-Hodgkin's)
Interventions: Device: CliniMACS CD34+ Reagent System;   Drug: Thiotepa;   Drug: Cyclophosphamide;   Drug: Alemtuzumab;   Drug: Tacrolimus;   Drug: Melphalan;   Drug: Busulfan;   Drug: Fludarabine;   Drug: Methylprednisolone

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-42) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.